Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Toronto

$436,050.00

Understanding the shifting landscape of Hepatitis B treatment in Canada

FY 2025-26

Summary
Hepatitis B is a serious liver infection caused by the Hepatitis B virus (HBV), and effective treatment is crucial for managing the disease and preventing severe health complications.Our project aims to provide a comprehensive overview of Hepatitis B treatment in Canada, focusing on recent developments over the past decade. We will explore several key areas including Current Treatment Landscape to better understand the state of Hepatitis B treatment in Canada, including the types of therapies used and in whom. We will explore if this differs by some populations and across Canada. We will also explore the impact of recent policy changes affecting reimbursement for Hepatitis B treatments will be analyzed. These policies play a critical role in determining which treatments are accessible to patients and how financial support affects their use. By examining these elements, our project seeks to understand how advancements in treatment and changes in healthcare policies have shaped the management of Hepatitis B in Canada. This insight will help identify areas for improvement and guide future healthcare strategies to ensure that patients receive the best possible care. We will integrate patient partners and knowledge users to ensure use of this work.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
564016
Name
Tadrous Mina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Health Services Evaluation & Interventions Research 2
Projecttitle
Understanding the shifting landscape of Hepatitis B treatment in Canada
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$436,050
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Drugs; Health Outcomes; Health Policy; Hepatitis B; Pharmaceutical; Pharmacoequity
Abstract
Hepatitis B is a serious liver infection caused by the Hepatitis B virus (HBV), and effective treatment is crucial for managing the disease and preventing severe health complications.Our project aims to provide a comprehensive overview of Hepatitis B treatment in Canada, focusing on recent developments over the past decade. We will explore several key areas including Current Treatment Landscape to better understand the state of Hepatitis B treatment in Canada, including the types of therapies used and in whom. We will explore if this differs by some populations and across Canada. We will also explore the impact of recent policy changes affecting reimbursement for Hepatitis B treatments will be analyzed. These policies play a critical role in determining which treatments are accessible to patients and how financial support affects their use. By examining these elements, our project seeks to understand how advancements in treatment and changes in healthcare policies have shaped the management of Hepatitis B in Canada. This insight will help identify areas for improvement and guide future healthcare strategies to ensure that patients receive the best possible care. We will integrate patient partners and knowledge users to ensure use of this work.
Competitiondate
202603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tadrous, Mina; Mendlowitz, Andrew B; Wong, William Wai Lun
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $436,050~ $0~